Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor

[1]  J. Cesbron,et al.  Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  J. McGrath,et al.  Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. , 2009, Journal of dermatological science.

[3]  K. Bork,et al.  Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. , 2009, The Journal of allergy and clinical immunology.

[4]  K. Bork,et al.  Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[5]  Q. Duan,et al.  Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. , 2009, The Journal of allergy and clinical immunology.

[6]  P. Tornero,et al.  Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III , 2009, Allergy.

[7]  F. Hentges,et al.  Angioedema and estrogen-dependent angioedema with activation of the contact system. , 2009, The Journal of allergy and clinical immunology.

[8]  D. N. Patel,et al.  Hereditary angioedema with normal C1 inhibitor. , 2008, The American journal of medicine.

[9]  J. Bartra,et al.  Oestrogen‐dependent hereditary angio‐oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment , 2008, Allergy.

[10]  C. Bell,et al.  First molecular confirmation of an Australian case of type III hereditary angioedema. , 2008, Pathology.

[11]  K. Bork,et al.  Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. , 2007, The American journal of medicine.

[12]  S. Cichon,et al.  Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. , 2007, The Journal of allergy and clinical immunology.

[13]  S. Cichon,et al.  A case of hereditary angio‐oedema type III presenting with C1‐inhibitor cleavage and a missense mutation in the F12 gene , 2007, The British journal of dermatology.

[14]  J. M. Vidal,et al.  Analgesia obstétrica en un caso de edema angioneurótico hereditario tipo III , 2007 .

[15]  S. Cichon,et al.  Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. , 2006, American journal of human genetics.

[16]  K. Bork.  Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. , 2006, Immunology and allergy clinics of North America.

[17]  P. Greenberger.  Anaphylactic and anaphylactoid causes of angioedema. , 2006, Immunology and allergy clinics of North America.

[18]  Miguel Park,et al.  Idiopathic recurrent angioedema. , 2006, Immunology and allergy clinics of North America.

[19]  M. Cicardi,et al.  Angioedema without urticaria: a large clinical survey , 2006, Canadian Medical Association Journal.

[20]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[21]  K. Bork,et al.  Hereditary angio‐oedema with normal C1 inhibitor in a family with affected women and men , 2006, The British journal of dermatology.

[22]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[23]  K. Bork,et al.  Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. , 2004, The American journal of medicine.

[24]  W. Klaustermeyer,et al.  New‐variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function , 2004, Allergy.

[25]  T. Krieg,et al.  Efficacy of danazol treatment in a patient with the new variant of hereditary angio‐oedema (HAE III) , 2004, The British journal of dermatology.

[26]  K. Binkley,et al.  Estrogen-dependent inherited angioedema. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[27]  K. Bork,et al.  Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.

[28]  K. Bork,et al.  Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. , 2003, The American journal of medicine.

[29]  A. Toutain,et al.  Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. , 2001, The Journal of allergy and clinical immunology.

[30]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[31]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[32]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[33]  M. Cicardi,et al.  Idiopathic nonhistaminergic angioedema. , 1999, The American journal of medicine.

[34]  B. Stricker,et al.  ACE Inhibitor-Induced Angioedema , 1998, Drug safety.

[35]  A. Black,et al.  Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema , 1997, The British journal of dermatology.

[36]  C. Hack,et al.  Structure/Function Analysis of Human Factor XII Using Recombinant Deletion Mutants , 1996 .

[37]  C. Hack,et al.  Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. , 1996, European journal of biochemistry.

[38]  C. L. La Porta,et al.  Control of human coagulation by recombinant serine proteases. Blood clotting is activated by recombinant factor XII deleted of five regulatory domains. , 1992, European Journal of Biochemistry.

[39]  M. Cicardi,et al.  Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. , 1991, The American journal of medicine.

[40]  R. MacGillivray,et al.  Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region. , 1987, The Journal of biological chemistry.

[41]  R T MacGillivray,et al.  Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. , 1985, The Journal of biological chemistry.